Vestal Point Capital’s Black Diamond Therapeutics BDTX Stock Holding History

Vestal Point Capital’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-870,000	Closed	-$2.11M	–	95
2025 Q4	$2.11M	Sell	870,000 -4,680,000	-84%	-$16.6M	0.07%	70
2025 Q3	$21M	Sell	5,550,000 -50,000	-0.9%	-$146K	0.95%	40
2025 Q2	$13.9M	Hold	5,600,000	–	–	0.73%	41
2025 Q1	$8.68M	Hold	5,600,000	–	–	0.62%	38
2024 Q4	$12M	Buy	5,600,000 +571,500	+11%	+$1.64M	0.71%	40
2024 Q3	$21.9M	Buy	5,028,500 +2,928,500	+139%	+$15.9M	1.66%	22
2024 Q2	$9.79M	Buy	+2,100,000	New	+$11.3M	0.73%	35

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vestal Point Capital's BDTX Position: Q1 2026 in Review

Vestal Point Capital sold out of Black Diamond Therapeutics (BDTX) in Q1 2026, closing a stake of 870,000 shares — an estimated $2.11M sold.

Vestal Point Capital first reported a position in BDTX in Q2 2024 and held it in 7 quarters. The position peaked at $21.9M in Q3 2024. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

Vestal Point Capital reported no remaining Black Diamond Therapeutics position as of Q1 2026 after selling out during the quarter.
Vestal Point Capital sold 870,000 Black Diamond Therapeutics shares in Q1 2026, an estimated $2.11M.
Vestal Point Capital first reported a position in Black Diamond Therapeutics in Q2 2024 and held it in 7 quarters.
Vestal Point Capital's Black Diamond Therapeutics position peaked at $21.9M in Q3 2024.
104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.